Key regions: France, India, United Kingdom, South Korea, Japan
The Multiple Sclerosis Drugs market in Uruguay has been experiencing a steady growth in recent years.
Customer preferences: Uruguayans suffering from Multiple Sclerosis (MS) have been showing a growing preference for disease-modifying therapies (DMTs) over symptomatic treatments. This shift in preference is driven by a desire to slow down the progression of the disease and reduce the frequency of relapses. Patients are also increasingly seeking treatments that have fewer side effects and are more convenient to use.
Trends in the market: The market for MS drugs in Uruguay is dominated by the use of injectable DMTs. However, there has been a recent trend towards the use of oral DMTs, which offer greater convenience for patients. The introduction of new oral DMTs in the market has also contributed to this trend. Another trend is the increasing use of biosimilars, which are more affordable versions of biologic drugs. This has led to greater competition in the market and has made treatment more accessible to a larger number of patients.
Local special circumstances: Uruguay has a small population and a relatively low prevalence of MS. This has limited the number of clinical trials conducted in the country, and as a result, there is a limited availability of drugs for the treatment of MS. Patients often have to rely on imported drugs, which can be expensive and may not be covered by insurance. In addition, there is a lack of specialized healthcare professionals in the country who can provide comprehensive care to MS patients.
Underlying macroeconomic factors: Uruguay has a stable economy and a well-developed healthcare system. The government provides universal healthcare coverage to its citizens, which includes coverage for the treatment of MS. However, the high cost of MS drugs and the limited availability of some drugs have put a strain on the healthcare system. The government has been taking steps to address this issue by negotiating with drug manufacturers to lower prices and by promoting the use of biosimilars.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
